OneSource Specialty Pharma Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jewrq4v5rc6e92f8xm7gkto3.pdf

Key Takeaways


The Revenue Recognition Overhang

Arun Kumar: "I just wanted to be on this call to caution our investors that everything is hunky-dory, but our numbers may not necessarily reflect the true nature of the work that we are doing and the business opportunities that we are sitting on."

DDC: The Capacity-Constrained Engine

Arun Kumar: "The adjusted capacity is a function of various factors, but the adjusted capacity will then be priced at a different price point depending upon the volumes. So consequently, your focus should be on our overall '28 guidance, which gives you a clear pathway."

Biologics & Injectables: The Next Legs


The End-to-End Moat

Neeraj Sharma: "Not only we do development for them, we will do commercial manufacturing for fill finish for cartridge, pack it, put it in the box, serialize it. So the box which a patient opens at home is the box coming out of one source site."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Phase 2 capacity ready22 crore units installed DDC capacityEnd of CY26 (pulled forward by ~1 year)
Some capacity online earlierPartial capacity additionMay or June
Canada semaglutide launchFirst wave of filers, active playerFrom March
India launchesExpect to be in market on day oneAs partner approvals come through
FY27 specific guidanceMore specific guidance for next year and beyondEnd of March, when non-Canada markets open
FY28 revenue outlook₹40 crore base business, ₹50 crore subject to shareholder approvalsReiterated
Biologics capacity expansionMammalian capacity from 4 kL to 8 kL with limited capexNo date (demand-driven)
Acquisition consolidationPoland and Brookes to start consolidatingNext financial year, subject to approvals
Working capital normalizationInventory buildup to unwindMedium-term

Key Metrics

MetricQ2 FY26
Revenue₹375.8 cr, +12% YoY
H1 FY26 revenue₹703 cr, +12% YoY
EBITDA₹106.5 cr, +37% YoY
EBITDA margin28%, expanded 506 bps YoY
H1 FY26 EBITDA₹195 cr, 28% margin
Adjusted PAT₹44.9 cr, versus negative PAT in prior-year quarter
Adjusted EPS (fully diluted)₹3.9 per share
Pro forma combined H1 revenue (OneSource plus incoming businesses)~US$110 mn, at ~30% EBITDA margin
FY28 revenue outlook₹50 cr (base business ₹40 cr plus inorganic), subject to shareholder approvals
Net debt₹903.3 cr, up ₹432.6 cr vs March 2025
Working capital₹593.6 cr, elevated due to planned inventory buildup for DDC launches
Effective interest rateDown 140 bps YoY, now in single digits
Customer and regulatory inspections (H1 FY26)37 successful inspections
New RFPs added in quarter26
Customers common across modalities12
Biologics funnel~4x of FY25 level
Installed biologics capacity (mammalian)4,000 liters, expandable to 8,000 liters with limited capex
DDC pen capacity targetOver 20 cr units ready by end of CY26, nearly a year ahead of prior schedule
Markets with patent expiry in March70+